AI Workflow for Synthetic Pharmacovigilance and Adverse Event Report Data

Manual acquisition of real adverse event reports for testing signal detection algorithms creates a critical bottleneck, delaying system validation and model deployment by months. This custom workflow automates the generation of synthetic Individual Case Safety Reports (ICSRs) that mirror real-world drug-event relationships, patient demographics, and temporal narratives. It enables safety teams to conduct unlimited, compliant stress-testing of platforms like Argus or ArisG, improving algorithm robustness and reducing reliance on sparse, sensitive real data. The operational upside is faster go-live for safety systems and more agile model iteration cycles.

Implementation integrates with Clinical Trial Management Systems (CTMS) and Electronic Data Capture (EDC) platforms like Medidata Rave for seamless test data ingestion. The architecture employs a multi-agent system where specialized generators handle demographics, drug exposure timelines, and outcome narratives, constrained by MedDRA ontologies and known drug-side effect profiles. A mandatory validation layer scores statistical fidelity against real-world distributions and flags anomalies for human review, ensuring clinical plausibility and privacy guarantees before data is released to downstream research or quality assurance environments.

This workflow replaces manual, sample-based testing of safety systems with an automated pipeline that generates unlimited, compliant Individual Case Safety Reports (ICSRs). It directly accelerates signal detection algorithm development and validation by providing tailored datasets that mirror known drug-event relationships and regulatory formats like E2B(R3). The operational upside comes from compressing months of data procurement into hours, enabling continuous testing and more robust model training without privacy exposure or contractual delays.

Implementation integrates this multi-agent system with existing pharmacovigilance platforms like Oracle Argus or ArisG, with the Orchestrator managing context passing and dependency resolution between specialized agents. Critical controls include the Validator agent enforcing clinical logic (e.g., lab value ranges, temporal impossibilities) and a mandatory human review gate for low-confidence or novel event associations. Observability is built in via detailed audit logs of each agent's decisions, supporting regulatory scrutiny and continuous pipeline optimization.

This workflow automates the generation of synthetic Individual Case Safety Reports (ICSRs) to eliminate the bottleneck of waiting for sparse, sensitive real-world data. By creating statistically realistic patient demographics, drug exposures, timelines, and outcome narratives, safety teams can stress-test E2B validation rules, train ML models for signal detection, and validate new reporting integrations continuously. The operational upside is a 70-80% reduction in the time-to-data for development cycles, directly accelerating time-to-market for safety system upgrades and new drug monitoring programs.

Implementation begins with Phase 1: ingesting and profiling historical, de-identified AE data to model drug-event relationships and reporting patterns. Phase 2 uses conditional generative models (e.g., GANs, LLMs) orchestrated via LangGraph to produce synthetic ICSRs. Each batch undergoes Phase 3 validation against statistical fidelity metrics and clinical plausibility rules; failures trigger automated retuning. Successful cohorts are formatted for E2B standards and delivered via API to test instances of safety databases like Oracle Argus or ArisG in Phase 4, with full audit logging for governance.

This workflow directly addresses the critical bottleneck in pharmacovigilance: the scarcity of real adverse event reports for validating signal detection algorithms and training AI models. By automating the creation of synthetic Individual Case Safety Reports (ICSRs), safety teams can generate unlimited, compliant test data that mirrors known drug-event associations, patient demographics, and temporal patterns. This eliminates months-long waits for sufficient real-world data, allowing for continuous development, stress-testing, and validation of monitoring systems, ultimately leading to faster, more robust safety surveillance.

Implementation requires a multi-agent architecture, typically built on LangGraph or CrewAI, where specialized agents handle demographic synthesis, drug-side effect rule application, and narrative generation in MedDRA-coded formats. The core is a validation engine that scores synthetic reports against real-world statistical distributions and privacy guarantees (e.g., k-anonymity) before release. Integration points include Electronic Data Capture (EDC) systems like Oracle Clinical and safety databases such as Argus for seamless ingestion. Governance is enforced through automated audit logging of all generation parameters and human review gates for low-confidence outputs.